LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles

Safety, tolerability, and pharmacology profiles of LY3127760, an EP4 antagonist, were explored in healthy subjects in a subject/investigator‐blind, parallel‐group, multiple‐ascending dose study. Cohorts consisted of 13 patients randomized to LY3127760, celecoxib (400 mg), or placebo (9:2:2 ratio) fo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Transl Sci
Autori principali: Jin, Yan, Smith, Claire, Hu, Leijun, Coutant, David E., Whitehurst, Kelly, Phipps, Krista, McNearney, Terry Ann, Yang, Xiao, Ackermann, Bradley, Pottanat, Thomas, Landschulz, William
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5759725/
https://ncbi.nlm.nih.gov/pubmed/28857461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12497
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi